Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications
Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursues regulatory approval for DehydraTECH-CBD for potential use as a treatment for hypertension HYPER-H21-4 will build on successes witnessed in initial human hypertension studies The company, which has a fully funded R&D budget, recently announced new R&D programs covering multiple conditions, including dementia, diabetes, and rheumatoid disease Lexaria is committed to improving lives and lessening deaths through its patented DehydraTECH(TM) technology With a fully-funded research and development (“R&D”) budget, Lexaria Bioscience (NASDAQ: LEXX), a global leader in enhancing the speed, efficacy, bioavailability, and brain absorption of…

















